On the line.

This multi-institutional retrospective look at 87 patients with leptomeningeal EGFR-mutated non-small cell lung cancer (NSCLC) progressing on an EGFR-TKI, 50 were re-challenged with a different EGFR-TKI or increased dose and achieved significantly better median survival (4 → 8 months). | Flippot, J thorac Oncol 2019